Biomx Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Biomx Inc (PHGE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Biomx Inc vs Its Competitors
- Profitability: Its -1,158.4% net margin compares with -23.5% for the peer group.
- Peer revenue share: Biomx Inc accounted for 0.0% of combined revenue among its tracked peer group.
- Structure: Biomx Inc operates in the following segments: All Other Segments.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PHGE Sales vs. its Competitors, Q2 2026
With a net margin of -1,158.43 %, Biomx Inc reported lower profitability than its competitors (-23.50 %).
Biomx Inc generated 0.00 % of the combined sales of its peer group.
API endpoints for this dataset
Biomx Inc vs. its Competitors, Q2 2026
Net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Biomx Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Biomx Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Biomx Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Biomx Inc's competitor groups requires a Commercial License.
Biomx Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Biomx Inc | - | - | - | Yes |
| Competitors combined (41) | ||||
| High-Confidence Competitors (5) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PHGE Stock Performance relative to its Competitors
PHGE Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Immunitybio inc | 282.9% | Outperformed |
| 4 | Revolution Medicines Inc | 282.9% | Outperformed |
| 5 | Kymera Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Biomx Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Biomx Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Biomx Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Biomx Inc |
0.73 | - |
 Amgen Inc |
250,468.48 | 38,095.00 |
 Gilead Sciences Inc |
208,779.39 | 30,988.00 |
 Vertex Pharmaceuticals Inc |
139,617.37 | 12,951.60 |
 Moderna Inc |
101,167.62 | 2,228.00 |
 Regeneron Pharmaceuticals Inc |
95,499.36 | 16,896.20 |
| SUBTOTAL | 981,955.41 | 122,474.74 |
Sign in to see all competitors of Biomx Inc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Biomx Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Biomx Inc's Competitors Named by the Company
Competitive relationships identified from Biomx Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Armata Pharmaceuticals, Inc. | Company report | 85% |
| Locus Biosciences, Inc. | Company report | 85% |
| SNIPR Biome | Company report | 85% |
| Phaxiam | Company report | 85% |
| Technophage | Company report | 85% |
| Pliant | Company report | 85% |
| Gilead | Company report | 85% |
| Acorda Therapeutics | Company report | 85% |
| Intercept | Company report | 85% |
Company report basis, confidence, active dates and source counts for Biomx Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Biomx Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Biomx Inc | All Other Segments 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Biogen Inc | Reportable 100.00 % |
| Illumina Inc | Sequencing 90.43 % |
| Exelixis Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Biomx Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Biomx Inc | 1 | - | -1,730,050 |
| Amgen Inc | 250,468 | 2,930,385 | 672,538 |
| Gilead Sciences Inc | 208,779 | 1,822,824 | -227,235 |
| Vertex Pharmaceuticals Inc | 139,617 | 31,979,259 | 9,817,037 |
| Moderna Inc | 101,168 | 474,043 | -670,426 |
| Regeneron Pharmaceuticals Inc | 95,499 | 1,096,444 | 312,615 |
| PEERS TOTAL | 981,955 | 1,767,491 | 106,400 |
Biomx Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 76.66 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Illumina Inc | United States and Canada 56.42 % |
| Exelixis Inc | United States 92.47 % |
| Immunitybio inc | United States 98.99 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Biomx Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 158 companies in Biomx Inc's industry classification, broader than the peer set above. Market cap in millions of $.Biomx Inc ranks #0 of 158 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,353, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 250,468 | 26.02 % |
| 2 | Gilead Sciences Inc | 207,444 | 21.55 % |
| 3 | Moderna Inc | 101,168 | 10.51 % |
| 4 | Argenx Se | 61,223 | 6.36 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Mesoblast Limited | 1,234 | 5.2% |
| 9 | Exelixis Inc | 1,234 | 5.2% |
| 10 | Neurocrine Biosciences Inc | 1,234 | 5.2% |
| 0 | Biomx Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Biomx Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-10-08.
Biomx Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.5x | - |
| EV / EBITDA | -0.2x | 16.7x | -16.8x |
| P/B | 0.2x | 5.1x | -4.9x |
| Return on Equity | -533.84 % | industry aggregate | -532.30 % |
| Return on Invested Capital | -59.81 % | -11.17 % (avg) | -48.64 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Biomx Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - |
| Return on Invested Capital | 22.43 % | 21.43 % | 31.08 % | 34.34 % | 36.78 % | 77.65 % | 16.79 % |
| P/E | 1,971.8x | - | 1.3x | - | 0.1x | 0.2x | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Biomx Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,353 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Biomx Inc's dedicated Suppliers and Customers pages, not here.
Biomx Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 532.3 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (65.90 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Biomx Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Biomx Inc | 0.66 | 0.82 | 0.07 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Gilead Sciences Inc | - | 1.52 | 1.47 |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Biomx Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Biomx Inc | Q2 2026 | - | - |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Gilead Sciences Inc | Q3 2026 | +6.8 % | -20.4 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| PEERS TOTAL | +12.4 % | -8.7 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Biomx Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Biomx Inc | Q2 2026 | - | - |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Gilead Sciences Inc | Q3 2026 | +0.1 % | +61.2 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
Biomx Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Biomx Inc | - | - | - |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Gilead Sciences Inc | - | - | - |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Moderna Inc | - | - | - |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Biomx Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Biomx Inc | - | - |
| Amgen Inc | 28.60 | 6.57 |
| Gilead Sciences Inc | - | 6.74 |
| Vertex Pharmaceuticals Inc | 35.27 | 10.78 |
| Moderna Inc | - | 45.41 |
| Regeneron Pharmaceuticals Inc | 20.00 | 5.65 |
| PEERS AVERAGE | 133.81 | 8.02 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.